Skip to notes
CJC-1295 Visit Notes

I read CJC-1295 research for what it actually measured

A study doesn't have to answer everything to be useful. I just want to know which question it answered. With CJC-1295, that's often a question about hormone activity rather than how someone feels.

I look for three things: which preparation was used, who took part and what changed. Those details help keep an interesting result from growing into a much bigger claim.

Dough rests beside a white bowl on an enamel counter while a baker’s hands rest at the edge.
A quiet surface in the middle of an ordinary afternoon.

The early findings were about hormones

Teichman and colleagues' research in healthy adults found that long-acting CJC-1295 raised growth hormone and IGF-1 for days. IGF-1 is a growth factor affected by growth hormone. The paper also estimated how long the peptide stayed in the body.

Ionescu and Frohman looked at growth hormone's rising-and-falling pattern. Those pulses continued while hormone levels increased. That helps explain the response, but it doesn't establish a benefit someone would notice in daily life.

I wouldn't use either finding as proof of better sleep, quicker recovery or slower aging. Those outcomes weren't measured in these studies. A hormone response is a finding with a specific job, not an answer to every hope attached to it.

The people and preparation matter

FDA's December 2024 review describes a small body of published human research in healthy adults, most receiving only one injection. It found no studies establishing effectiveness for people with growth hormone deficiency. Long-term safety was unknown.

FDA also found no human studies of the forms without DAC. DAC is the added part that attaches to albumin, a blood protein, and helps the peptide remain in circulation longer. The published human work appeared to use that form, although the exact salt wasn't specified.

That leaves a simple question for any claim: does this paper match the preparation and the person being discussed? I keep the full-name notes nearby rather than assume that it does.

An unfinished trial stays unfinished

The trial registry records a study in people with HIV and excess abdominal fat. It was terminated and has no posted results. A planned study tells us what researchers wanted to test; it doesn't give us a successful outcome to report.

Safety needs the same care. FDA's review discusses heart-rate and blood-pressure changes, immune concerns and missing long-term information. One reassuring sentence in a small paper can't settle all of that.

My notes end with two questions: “What did this show?” and “What didn't it test?” The sources page makes it easy to check, and the effects page brings those limits back to ordinary concerns.